Sfoglia per AUTORE
MASINI C
Collezione AO Ordine Mauriziano

  

Items : 9

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Epub 2024 Nov 10.

2025
ASL Cuneo 2
AO Ordine Mauriziano

Puglisi S; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Napoli MD; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Merler S; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Sbrana A; Chiellino S; De Giorgi U; Maruzzo M; et alii...

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). in Future oncology (London, England) / Future Oncol. 2024 May 3:1-19. doi: 10.1080/14796694.2024.2340960.

2024
AO Ordine Mauriziano

Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE;

The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO). in Tumori / Tumori. 2024 Jun;110(3):203-208. doi: 10.1177/03008916231222761. Epub 2024 Feb 7.

2024
AO Ordine Mauriziano

Speranza D; Sapuppo E; Aprile G; Auriemma A; Bergamo F; Bianco R; Bordonaro R; Brandi G; Brunetti O; Carnaghi C; Ciliberto D; Cinieri S; Corallo S; De Vita F; Di Donato S; Ferraù F; Fornaro L; Barucca V; Giommoni E; Lotesoriere C; Luchini C; Masini C; Niger M; Pisconti S; Rapposelli IG; Rimassa L; Rognone C; Rodriquenz MG; Corsini LR; et alii...

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Jul 2;73(9):161. doi: 10.1007/s00262-024-03741-2.

2024
AO Ordine Mauriziano

Messina C; Catalano M; Roviello G; Gandini A; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucal PA; Masini C; Naglieri E; Procopio G; Milella M; Catalano F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Soraru M; Prati V; Atzori F; Di Napoli M; Messina M; Morelli F; Prati G; Nole F; Malgeri A; Tudini M; et alii...

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Di Napoli M; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Milella M; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Chiellino S; Bimbatti D; De Giorgi U; Rebuzzi SE; et alii...

Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). in Future oncology (London, England) / Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12.

2024
AO Ordine Mauriziano

Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE;

Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. in European urology / Eur Urol. 2023 Jan;83(1):82-89. doi: 10.1016/j.eururo.2022.09.025. Epub 2022 Oct 8.

2023
AO Ordine Mauriziano

Procopio G; Lolli C; Di Napoli M; Pignata S; Ignazzi G; Gamba T; Veccia A; Scandurra G; Hamzaj A; Ermacora P; Masini C; Aieta M; Atzori F; Stellato M; Carella C; Bimbatti D; Giannatempo P; De Giorgi U; Vignani F; Tambaro R; Pierantoni F; Zonno A; Santini D; Di Maio M;

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2021 May 18;13:17588359211019642. doi: 10.1177/17588359211019642. eCollection 20

2021
AO Ordine Mauriziano

Bersanelli M; Casadei C; Pierantoni F; Roviello G; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Messina C; Messina M; Pignata S; Atzori F; Stellato M; Soto Parra HJ; Prati V; Santoni M; Cortellini A; Sorarù M; Mollica V; Panni S; Ricotta R; Baldessari C; Fratino L; Tomasello L; Merler S; Procopio G; Naglieri E; Masini C; et alii...

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Feb;17(1):e150-e155. doi: 10.1016/j.clgc.2018.10.001. Epub 2018 Oct 10.

2019
AO Ordine Mauriziano

Masini C; Vitale MG; Maruzzo M; Procopio G; de Giorgi U; Buti S; Rossetti S; Iacovelli R; Atzori F; Cosmai L; Vignani F; Prati G; Scagliarini S; Guida A; Berselli A; Pinto C;